Mucormycosis, often known as black fungus, is a fungal infection caused by the mucormycetes fungi. Zygomycetes is a class of fungi. Mucormycetes, the fungus that cause mucormycosis, are found all throughout the world, especially in soil and in decaying organic waste like leaves, compost piles, and animal dung. It is not contagious and cannot be passed from one person to another. Mucormycosis (also known as zygomycosis) is a dangerous but uncommon fungal infection caused by a fungus known as mucormycetes. Molds can be found all over the place. Mucormycosis is a fungal infection that primarily affects persons who have health issues or who use medications that reduce the body's capacity to resist infections and illness. Infections are most typically acquired when mould spores are inhaled or, less commonly, when spores enter the body through a cut in the skin. It takes place after COVID-19. Home remedies, such as consuming probiotics, and foods that promote immunity, can help to minimise mucormycosis. The main purpose of this review Related to Mucormycosis is to diminish the growth of Mucormycosis by taking Ayurvedic Treatment.
Cite this article:
S.D. Mankar, Waditake Poonam, Prajakta Jejurkar. Review on Mucormycosis: It is a life Threatening infection. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(4):316-8. doi: 10.52711/2231-5659.2021.00049
S.D. Mankar, Waditake Poonam, Prajakta Jejurkar. Review on Mucormycosis: It is a life Threatening infection. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(4):316-8. doi: 10.52711/2231-5659.2021.00049 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2021-11-4-9
1. Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clinical Infectious Diseases, 2012; 54(suppl_1): S8-15.
2. Mohammadi R, Nazeri M, Sayedayn SM, Ehteram H. A successful treatment of rhinocerebral mucormycosis due to Rhizopus oryzae. Journal of research in medical: The Official Journal of Isfahan University of Medical Sciences, 2014; 19(1): 72.
3. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clinical Infectious Diseases, 2005; 41(5): 634-53.
4. Bitar D, Van Cauteren D, Lanternier F et al. Increasing incidence of zygomycosis (mucor-mycosis), France,1997–2006. Emerg Infect Dis., 2009; 15: 1395–1401.
5. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clinical Infectious, 2012; 54(suppl_1): S23-34.
6. Waldorf AR. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol Ser., 1989; 47: 243–271
7. Rammaert B, Lanternier F, Poirיe S, Kania R, Lortholary O. Diabetes and mucormycosis: a complex interplay. Diabetes & metabolism, 2012; 38(3): 193-204.
8. Meyer BR, Wormser G, Hirschan SZ, et al. Rhinocerebral mucormycosis: premortem diagnosis and therapy. Arch. Intern. Med., 1979; 139: 557.
9. Gale GR, Welch AM. Studies of opportunistic fungi. I. Inhibition of Rhizopus oryzae by human serum. Am. J. Med. Sci., 1961; 241: 604–12.
10. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J. Clin. Invest., 1984; 74: 150 60.
11. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann. Thorac. Surg., 1994; 57(4): 1044- 50.
12. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N. Engl. J Med., 1999; 341(25): 1906- 12.
13. Bhansali A, Sharma A, Kashyap A, Gupta A, Dash RJ. Mucor endophthalmitis. Acta Ophthalmol Scand., 2001; 79(1): 88- 90.
14. Tsaousis G, Koutsouri A, Gatsiou C, Paniara O, Peppas C, Chalevelakis G. Liver and brain mucormycosis in a diabetic patient type II successfully treated with liposomal amphotericin B. Scand. J. Infect. Dis., 2000; 32(3): 335- 7.
15. Waldorf AR, Levitz SM, Diamond RD. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J. Infect. Dis., 1984; 150(5): 752-60.
16. Artis WM, Fountain JA, Delcher HK. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes, 1982; 31: 109–14.
17. Cohen SG, Greenberg MS. Rhinomaxillary mucormycosis in a kidney transplant patient. Oral Surg. Oral Med. Pathol., 1980; 50: 33–8.
18. Marchevskey AM, Bottone EJ, Geller SA. The changing spectrum of disease etiology and diagnosis of mucormycosis. Human Pathology, 1980; 11: 457.